Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years

Carlos M de Castro, Brian Mulherin, Christopher J. Patriquin, Veena Selvaratnam, Raymond SM Wong, Richard J. Kelly, Lisa Tan, Peter Hillmen, Dale Zhang, Jessica Savage, Regis Peffault De Latour

Blood (2023) 142 (Supplement 1): 574.

https://doi.org/10.1182/blood-2023-181054

Published: 2023

Journal Articles

Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)

Bernd Jilma, Eloy Roman, Yasutaka Ueda, Silvia Mappa, Johan Szamosi, Jessica Savage, Alexander Roeth

Blood (2022) 140 (Supplement 1): 5326–5327.

https://doi.org/10.1182/blood-2022-155989

Published: 2022

Journal Articles

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Morag Griffin, Richard Kelly, Dries Deeren, Yeow Tee Goh, Eric Tse, Kensuke Usuki, Raymond Wong, Regina Horneff, Lisa Tan, Michael Yeh, Jessica Savage, Jeff Szer

Blood (2022) 140 (Supplement 1): 2937–2939.

https://doi.org/10.1182/blood-2022-163117

Published: 2022

Journal Articles

Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria

Christopher J. Patriquin, Andrija Bogdanovic, Morag Griffin, Richard Kelly, Jaroslaw P. Maciejewski, Brian Mulherin, Régis Peffault de Latour, Alexander Roeth, Veena Selvaratnam, Jeffrey Szer, Jessica Savage, Regina Horneff, Lisa Tan, Michael Yeh, Jens Panse

Blood (2022) 140 (Supplement 1): 2921–2923.

https://doi.org/10.1182/blood-2022-163625

Published: 2022

Journal Articles

Developing an in Vitro Functional Model of Allergic Transfusion Reactions

William Savage, MD, PhD, Aaron A. R. Tobian, MD, PhD, Jessica Savage, MD MHS, Chris Thoburn, Paul M. Ness, MD, John T. Schroeder, PhD

Blood (2012) 120 (21): 3426.

https://doi.org/10.1182/blood.V120.21.3426.3426

Published: 2012

NARROW

Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years

Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria

Developing an in Vitro Functional Model of Allergic Transfusion Reactions

Email alerts

ASH Publications

American Society of Hematology

Efficacy and Safety Is Maintained in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for up to 3 Years

Trial in Progress: Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CASCADE)

Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study

Long-Term Safety and Efficacy of Pegcetacoplan Treatment in Adults with Paroxysmal Nocturnal Hemoglobinuria

Developing an in Vitro Functional Model of Allergic Transfusion Reactions

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only